Germany's Growth Story
This article was originally published in Start Up
Executive Summary
Germany's biotech investment has propelled a handful of companies onto the public markets a lot sooner than their US or UK counterparts. These German companies have followed aggressive acquisition strategies, most often buying into the US, sometimes using newly-minted Neuer Markt paper. Some are seeking through these acquisitions to both broaden their technology platform and acquire a product portfolio, hoping thereby to avoid the pitfalls of a narrow focus. It's too early to tell whether such a dual model will work. But the fact that Germany's young companies are finding their own approach to competing globally shows that the country's biotech initiative has already had some success.
You may also be interested in...
Public Venture Capital for Israel's Biotech Industry
Israeli biotech is hot -- lots of ideas and lots of entrepreneurs. But the industry is chronically short of management and venture money. For the latter, companies have turned to Israel's recently deregulated stock market.
Public Venture Capital for Israel's Biotech Industry
Israeli biotech is hot -- lots of ideas and lots of entrepreneurs. But the industry is chronically short of management and venture money. For the latter, companies have turned to Israel's recently deregulated stock market.
The IP Land Grab: New UK Tech Transfer Models
As VCs continue to woo later-stage assets, a new breed of companies has stepped in upstream to help UK universities commercialize their IP. The models vary, and it's unclear how successful they'll be either for investors, or for universities. But the attention and money they're attracting to the area are welcome.